BioInnovation Institute
Description
BioInnovation Institute (BII) is a leading non-profit foundation based in Copenhagen, Denmark, dedicated to fostering innovation in the life sciences. Established with a significant grant from the Novo Nordisk Foundation, BII operates as an incubator and accelerator, providing crucial support to entrepreneurs and researchers aiming to translate groundbreaking scientific discoveries into viable solutions for human and planetary health. Unlike traditional venture capital firms, BII primarily offers convertible loans and grants, coupled with extensive business development, scientific, and legal mentorship, creating a comprehensive ecosystem for early-stage and scaling biotech ventures.
BII's core offerings include two flagship programs: Venture Lab and Venture House. The Venture Lab program is designed for early-stage life science projects, providing a convertible loan of EUR 500,000 (approximately USD 540,000) to help de-risk and validate scientific concepts and build initial business cases. For more mature startups ready to scale, the Venture House program offers a larger convertible loan of EUR 1.3 million (approximately USD 1.4 million), focusing on accelerating product development and market entry. These structured funding mechanisms are complemented by access to state-of-the-art lab facilities and a network of industry experts.
Since its inception in 2018, BioInnovation Institute has demonstrated a significant impact on the Nordic life science landscape. The institute has supported over 100 projects and companies, contributing to the development of novel therapeutics, diagnostics, and sustainable bio-industrial solutions. With a total commitment of over DKK 1 billion (approximately USD 145 million) in funding, BII plays a pivotal role in bridging the gap between academic research and commercialization, nurturing a new generation of life science companies and driving innovation from Scandinavia to the global stage.
Investor Profile
BioInnovation Institute has backed more than 67 startups, with 2 new investments in the last 12 months alone. The firm has led 60 rounds, about 90% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Convertible Note, Pre Seed, Debt Financing rounds (top funding stages).
- Majority of deals are located in Denmark, Switzerland, Germany.
- Strong thematic focus on Biotechnology, Medical, Health Care.
- Led 1 rounds in the past year.
- Typical check size: $540K – $1.4M.
Stage Focus
- Convertible Note (78%)
- Pre Seed (7%)
- Debt Financing (6%)
- Grant (3%)
- Seed (3%)
- Angel (1%)
- Series Unknown (1%)
Country Focus
- Denmark (76%)
- Switzerland (4%)
- Germany (4%)
- The Netherlands (3%)
- United Kingdom (3%)
'%3e%3cpath fill='%23012169' d='M0 0v30h60V0z'/%3e%3cpath stroke='%23fff' stroke-width='6' d='m0 0 60 30m0-30L0 30'/%3e%3cpath stroke='%23C8102E' stroke-width='4' d='m0 0 60 30m0-30L0 30' clip-path='url(%23b)'/%3e%3cpath stroke='%23fff' stroke-width='10' d='M30 0v30M0 15h60'/%3e%3cpath stroke='%23C8102E' stroke-width='6' d='M30 0v30M0 15h60'/%3e%3c/g%3e%3c/svg%3e)
- United States (1%)
- Belgium (1%)
- Finland (1%)
- Iceland (1%)
Industry Focus
- Biotechnology
- Medical
- Health Care
- Therapeutics
- Medical Device
- Life Science
- Biopharma
- Food Processing
- Agtech
- Alternative Protein
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
